You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Validation of a salivary miRNA diagnostic test for autism spectrum disorder

    SBC: Quadrant Biosciences Inc.            Topic: 105

    Project Summary Abstract Autism spectrum disorder ASD is a continuum of neurodevelopmental characteristics that includes deficits in communication and social interaction as well as restrictive repetitive interests and behaviors ASD is an increasing public health concern with about in American children diagnosed with ASD in a fold increase in prevalence over the past years T ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Using Structuring Interacting RNAs (sxRNAs) as microRNA Inhibitors

    SBC: HocusLocus Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): We propose developing a trans-molecular RNA-switch for scientists to negatively affect the activity of endogenous microRNA for use as a molecular tool or therapeutic, an anti-miR. Since the discovery of miRNA, the creation of effective anti-miRs has been important, first to study and verify miRNA interactions, and, secondly, as a therapeutic tool. But, creating ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Therapy for drug resistant influenza strains by nucleic acid targeting of respiratory airways

    SBC: Abcombi Biosciences Inc            Topic: NIAID

    PROJECT SUMMARY Antiviral drugs are a crucial countermeasure for influenza A virus IAV particularly in circumstances of increased IAV incidence or if a vaccine is unavailable e g virulent H N IAV However the emergence of IAV strains that are resistant to current antivirals H N underscores the need for new treatment strategies particularly those that modify the host response IAVs ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Targeted Epigenetic Therapy for Triple-Negative Breast Cancer

    SBC: PARKSIDE SCIENTIFIC INC.            Topic: 102

    DESCRIPTIONprovided by applicantTriple negative breast cancerTNBCis one of the most aggressive forms of human cancerand currently has no targeted therapyChemotherapy is the only available treatment for TNBC patientsbut is deleterious and not effective once tumor spreadsTNBC represents a major unmet medical needaboutof breast cancer incidenceswomen worldwide inare TNBCTNBC disproportionally affects ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Small Molecule Antibiotic Potentiators for Drug-Resistant Bacteria

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant An estimated two million Americans suffer from infections caused by multi drug resistant MDR bacteria resulting in a substantial impact on patientsandapos lives and an extraordinary economic burden Due to the arsenal of antibiotic resistance mechanisms that these bacteria present traditional antibiotic therapies are often ineffective New strategies that u ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Smaller, Brighter Probes for Correlative Super-resolution and Electron Microscopy

    SBC: NANOPROBES INC            Topic: NIGMS

    DESCRIPTION provided by applicant We propose new probes for correlative super resolution fluorescence and electron microscopy that use biorthogonal reactions Click SNAP and HALO tags to label targets in living cells To minimize quenching of the fluorophores by the gold particles the small Undecagold gold atoms gold cluster label will be used this has minimal absorption at wavelengt ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. SHAPE RNA Bioinformatics for Therapeutics and Translational Research

    SBC: Ribometrix LLC            Topic: 400

    DESCRIPTION provided by applicant Only of the human genome is translated into proteins whereas roughly is transcribed into RNA Complex higher order structures in these RNAs fundamentally affect critical biological processes As examples RNA structures in the ribosome are the targets of many antibiotics structures in the genomes of RNA viruses like HIV and influenza are essential for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Screening the Ribosome for New Target Sites

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Nucleic acids are avenues for drug design both as therapeutics and as targets Here we propose to establish new methods for identifying antibiotic ribosome targets and lead compounds Targeting specific RNA such as rRNA which are involved in proliferation and survival of bacteria is a promising approach We are developing fast and low cost methods to screen s ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Science Take-Out Kits for Environmental Health Education

    SBC: Science Take-Out, LLC            Topic: NIEHS

    DESCRIPTION provided by applicant Nearly percent of death and disease worldwide is linked to environmental factors WHO therefore it is critical that the general public has basic understanding of how the environment affects their health and how they might protect themselves against environmental exposures Unfortunately environmental health content is typically covered on a very ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Recombinant Botulinum Neurotoxin for Treatment of Spastic Disorders

    SBC: Cytodel, Inc.            Topic: NINDS

    DESCRIPTION (provided by applicant): Botulinum neurotoxin (BoNT) is the active ingredient in pharmaceutical products like Botox(R) (Allergan), which FDA has approved for therapeutic and aesthetic indications. Because of its inherent toxicity,the dose of BoNT required to treat spasticity disorders in large muscle groups is uncomfortably close to the toxic dose range. ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government